41 completed, 3 active not recruiting, 2 terminated, 2 unknown. 49 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 49 | Completed 41, Active not recruiting 3, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 9 | Completed 8, Active not recruiting 1 |
Follow Furosemide: new trials by email Literature Review of Furosemide trials Research Report on Furosemide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) Rosuvastatin, Furosemide, MK-2828 - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 41 | 2026-03-18 | 2026-09-08 |
| Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 HRS-8427 injection plus furosemide, HRS-8427 injection plus metformin - Health Volunteer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2025-07-15 | 2025-08-28 |
| Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib Saruparib, Digoxin, Furosemide - Advanced Solid Malignancies | Phase 1 | Active not recruiting | AstraZeneca | 41 | 2025-03-25 | 2026-10-01 |
| A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood Zongertinib, Dabigatran-etexilate, Rosuvastatin - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 32 | 2024-08-20 | 2026-01-09 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants AZD4144- Part A, Placebo- Part A, AZD4144- Part B - Healthy Participants | Phase 1 | Completed | AstraZeneca | 91 | 2024-07-15 | 2025-07-04 |
| Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. Furosemide Injection - Acute Heart Failure | Phase 1 / Phase 2 | Completed | Johannes Grand | 20 | 2023-09-01 | 2024-02-16 |
| A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects Savolitinib, Digoxin, Metformin Hydrochloride - Healthy Male Subjects | Phase 1 | Completed | AstraZeneca | 6 | 2023-04-25 | 2023-07-13 |
| Voxelotor CYP and Transporter Cocktail Interaction Study Voxelotor, Bupropion, Repaglinide - Sickle Cell Disease | Phase 1 | Completed | Pfizer | 44 | 2023-04-17 | 2024-11-22 |
| Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma OBX-115, Acetazolamide, Cyclophosphamide - Tumor, Metastatic Melanoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 21 | 2022-09-07 | 2026-10-07 |
| Salt-Sensitivity and Immunity Cell Activation Furosemide 40 mg - High Blood Pressure, Salt; Excess | Phase 1 / Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 20 | 2021-09-01 | 2025-10-21 |
| Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide CHF Patients: ER Torsemide 40 mg, CHF Patients: Furosemide 40 mg - Body Weight Changes | Phase 1 | Terminated | Sarfez Pharmaceuticals, Inc. | 20 | 2021-06-30 | 2026-04-24 |
| Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) SHR4640 tablets and furosemide tablets - Healthy Male Subjects | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2021-06-28 | 2022-07-11 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants BMS-986308, Placebo (for BMS-986308), Furosemide - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 46 | 2021-04-14 | 2022-04-27 |
| A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body BI 730357, CRESTOR®, Lenoxin® - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2020-10-20 | 2023-09-06 |
| Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, Medfusion 3500 (v6) precision infusion pump - Heart Failure | Phase 1 / Phase 2 | Completed | SQ Innovation, Inc. | 20 | 2020-10-17 | 2026-06-15 |
| Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function Furosemide Injection, Creatinine Powder, Iohexol - Chronic Kidney Failure | Phase 1 | Completed | Instituto Nacional de Cardiologia Ignacio Chavez | 50 | 2020-03-03 | 2024-12-17 |
| An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability Furosemide 80 mg (8 mg/mL) - Healthy | Phase 1 | Completed | scPharmaceuticals, Inc. | 39 | 2019-12-02 | 2020-07-10 |
| Aerosol Particle Size and Breathing Pattern During Inhaled Furosemide Inhaled furosemide - Healthy Volunteers | Phase 1 | Unknown | Oxford Brookes University | 20 | 2019-10-14 | 2019-10-18 |
| Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide Water, Parmalat™ Whole Milk, Similac Pro-Advance™ - Medication Absorption | Phase 1 | Withdrawn | Yale University | 2018-12-31 | 2019-01-18 | |
| Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) MT-1186, Rosuvastatin, Sildenafil - Healthy Adult Subjects | Phase 1 | Completed | Shionogi | 84 | 2018-10-17 | 2026-07-15 |
Showing 20 of 49. Sign in to see all of them.
Heart Failure (8) · Dyspnea (4) · Cardiomyopathies (2) · Diabetes Mellitus (2) · Renal Insufficiency (2) · Anemia, Sickle Cell (1) · Body Weight Changes (1) · Diabetes Mellitus, Type 2 (1) · Edema (1) · Hodgkin Disease (1) · Hypercapnia (1) · Hypertension (1) · Inflammation (1) · Kidney Failure, Chronic (1) · Leukemia (1)
Boehringer Ingelheim (6) · AstraZeneca (3) · Yale University (3) · Beth Israel Deaconess Medical Center (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Merck Sharp & Dohme LLC (2) · Oxford Brookes University (2) · scPharmaceuticals, Inc. (2) · Actinium Pharmaceuticals (1) · Adrian Hernandez (1) · Akebia Therapeutics (1) · Ardea Biosciences, Inc. (1) · Astellas Pharma Europe B.V. (1) · Bial - Portela C S.A. (1) · Bristol-Myers Squibb (1)
United States (21) · Germany (8) · United Kingdom (5) · Canada (3) · China (3) · Bulgaria (1) · Denmark (1) · France (1) · India (1) · Japan (1) · Mexico (1) · Moldova (1) · Netherlands (1) · Puerto Rico (1) · Romania (1)
Jeffrey Testani, MD (2) · Adrian Hernandez, MD (1) · Alain Mina, M.D. (1) · Anil K, MD (1) · Annelize Koch, Dr (1) · Annet Kirabo (1) · Avinash Desai, MD (1) · Bruce G Rankin, DO, CPI, FACOFP (1)
PMID 25262369, PMID 28685495, PMID 30236110, PMID 33704925, PMID 33782832, PMID 35357290, PMID 36376130, PMID 36896716, PMID 37804170, PMID 38903022, PMID 39219444, PMID 40126554, PMID 40331908, PMID 40938670, PMID 41773006, PMID 41773934
2014 (2), 2015 (2), 2016 (2), 2017 (2), R01NR012009 (2), P01HL076611 (1), R01HL084155 (1), R01HL128973 (1), UL1TR000135 (1)